Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study

Cancer

Volumn 97, Issue 8, 2003, Pages 1991-1998

  Sorensen, Keld ^a   Levitt, Gill A ^b   Bull, Catherine ^b   Dorup, Inge ^a   Sullivan, Ian D ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Anthracyclines; Cancer; Cardiotoxicity; Children; Echocardiography

Indexed keywords

ANTHRACYCLINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE; ARTICLE; BODY GROWTH; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART PERFORMANCE; HEART STRESS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS;

ANTIBIOTICS, ANTINEOPLASTIC; CHILD, PRESCHOOL; COHORT STUDIES; DAUNORUBICIN; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART DISEASES; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; WILMS TUMOR;

EID: 0344407446     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11274     Document Type: Article

References (25)

1. Truesdell SC, Schwartz CL, Clark E, Constine LS. Cardiovascular effects of cancer therapy. In: Schwartz CL, Hobbie WL, Constine LS, Ruccione KS, editors. Survivors of childhood cancer, assessment and management. New York: Mosby; 1994:159-175
2. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
3. Levitt GA, Bunch K, Rogers CA, et al. Cardiac transplantation in childhood cancer survivors in Great Britain. Eur J Cancer 1996;32:826-830.
4. Nysom K, Colan SD, Lipshultz SE. Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog Pediatr Cardiol. 1998;8:121-138.
5. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
6. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracycline in girls. Med Pediatr Oncol. 1993;21:477-479.
7. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia; issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61-68.
8. Pinkerton CR, Bowman A, Holtzel H. Intensive consolidation chemotherapy for lymphoblastic leukaemia (UKALL X pilot study). Arch Dis Child. 1987;62:12-18.
9. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALLX. Lancet. 1995;345:143-145.
10. Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I. Cardiac function in Wilms' tumor survivors. J Clin Oncol. 1995;13:1546-1556.
11. Pritchard J, Imeson J, Barnes J, et al. Results of the United Kingdom Children's Study Group 1st Wilms' Tumour Study. J Clin Oncol. 1995;13:124-133.
12. Iwahara M, Benson LN, Freedom RM. Noninvasive estimation of end-systolic aortic pressure in children. Echocardiography. 1991;8:559-562.
13. Grossman W, Jones D, McLaurin LP. Wall stress and pattern of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
14. Colan SM, Borow KM, Neumann A. The left ventricular end-systolic wall stress velocity of fibre shortening relation: A load independent index of myocardial contractility. J Am Coll Cardiol. 1984;4:715-724.
15. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child. 1995;73:25-29.
16. Nysom, K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukaemia. J Clin Oncol. 1998;16:545-550.
17. Billingham ME, Masek MA. The pathology of anthracycline cardiotoxicity in children, adolescents and adults. In: Bricker JT, Green DM, D'Angio GJ. Cardiac toxicity after anthracycline treatment for childhood cancer. New York: Wiley-Liss, 1993:17-24.
18. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 2001;19:1926-1934.
19. Bozkurt B. Medical and surgical therapy for cardiac remodeling. Curr Opin Cardiol. 1999;14:196-205.
20. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in children: relation with systolic function, symptoms, and pathophysiology. Br Heart J. 1995;73:340-350.
21. Steinhertz LJ, Steinhertz PG, Tan CT. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677.
22. Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with antracyclines and chest radiation. Eur J Cancer. 1996;32A:97-103.
23. Uruena M, Stanhope R, Chessells JM, Leiper AD. Impaired pubertal growth in acute lymphoblastic leukaemia. Arch Dis Child. 1991;66:1403-1407.
24. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor study. J Clin Oncol. 1998;16:3628-3633.
25. Levitt GA. Cardioprotection. Br J Haematol. 1999;106:860-869.